Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- finCATIndependent statistical analysis of A Study of Cognitive Adaptation Training in Inpatient Forensic Environments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04294719).
- FINCH 1Independent statistical analysis of Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate: primary endpoint results, effect estimate with confidence…
- Finding an Optimal Latency for Paired Associative Stimulation in People With Chronic Stroke: Complete Statistical AnalysisIndependent statistical analysis of Finding an Optimal Latency for Paired Associative Stimulation in People With Chronic Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- FINESTIndependent statistical analysis of Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- FireballIndependent statistical analysis of A Study of Osseotite Certain Prevail Implants Used to Support Short Fixed Bridges With Immediate Occlusal Loading.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- FIREFLEYEIndependent statistical analysis of Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- FIRSTIndependent statistical analysis of Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma: primary endpoint results, effect estimate with…
- First – In – Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism: Complete Statistical AnalysisIndependent statistical analysis of First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism: primary endpoint results, effect…
- First HeroesIndependent statistical analysis of First Heroes: Engaging Fathers in the First 1000 Days: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04477577).
- First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: Complete Statistical AnalysisIndependent statistical analysis of First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: primary endpoint results, effect estimate with confidence interval,…
- First in Human Study to Assess Safety of VIS649 in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of First in Human Study to Assess Safety of VIS649 in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- First in Man Trial of BI 113608: Complete Statistical AnalysisIndependent statistical analysis of First in Man Trial of BI 113608: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01540825).
- First Line Therapy for Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of First Line Therapy for Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00456846).
- First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study: Complete Statistical AnalysisIndependent statistical analysis of First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study: primary endpoint…
- First-HDIndependent statistical analysis of First Time Use of SD-809 in Huntington Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01795859).
- First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration: Complete Statistical AnalysisIndependent statistical analysis of First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Complete Statistical AnalysisIndependent statistical analysis of First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High…
- First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221: Complete Statistical AnalysisIndependent statistical analysis of First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01524991).
- First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- FIRSTANAIndependent statistical analysis of Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH): Complete Statistical AnalysisIndependent statistical analysis of Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- FitMi PD Home Therapy for Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of FitMi PD Home Therapy for Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05655377).
- FITSTART+Independent statistical analysis of Parent Feedback Intervention Targeting Student Transitions and Alcohol Related Trajectories (+) Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691): Complete Statistical AnalysisIndependent statistical analysis of Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691): primary endpoint results, effect estimate with confidence…
- Flatbush FHC Proactive Colorectal Cancer Screening and Navigation: Complete Statistical AnalysisIndependent statistical analysis of Flatbush FHC Proactive Colorectal Cancer Screening and Navigation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05646355).
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FLAURA2Independent statistical analysis of A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2): primary endpoint results,…
- FlavanolIndependent statistical analysis of Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02943096).
- FLAXPADIndependent statistical analysis of Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- FLEXIndependent statistical analysis of Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Flex HDIndependent statistical analysis of Feasibility Study of The Use of FLEX HD® Surgical Implant or STRATTICE® Reconstructive Tissue Matrix in The Closure of Abdominal Wall Defects With Component Separation in Clean or…
- FLEX MIndependent statistical analysis of A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- FLEX VIndependent statistical analysis of A Study in Participants With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01202773).
- Flex-UpIndependent statistical analysis of A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence…
- Florbetapir Calibration to the Centiloid Scale: Complete Statistical AnalysisIndependent statistical analysis of Florbetapir Calibration to the Centiloid Scale: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02120664).
- FLOREYIndependent statistical analysis of Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Complete Statistical AnalysisIndependent statistical analysis of Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- FLOWIndependent statistical analysis of the FLOW phase 3 trial of semaglutide versus placebo in people with type 2 diabetes and chronic kidney disease, including trial design, the composite renal endpoint, Cox proportional-hazards…
- FLOWIndependent statistical analysis of A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease: primary endpoint results, effect estimate with confidence…
- FLUBUTBIIndependent statistical analysis of Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01366612).
- Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight: Complete Statistical AnalysisIndependent statistical analysis of Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders: Complete Statistical AnalysisIndependent statistical analysis of Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders: primary endpoint results, effect estimate…
- Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia: Complete Statistical AnalysisIndependent statistical analysis of Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia: primary endpoint results, effect estimate with…
- Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders: Complete Statistical AnalysisIndependent statistical analysis of Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders: primary endpoint results, effect estimate with confidence interval,…
- Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma:…
- Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…